Tevogen Bio posts 51% reduction in nine-month operating loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
November 14, 2025 2:32 PM ESTWARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (Tevogen Bio Holdings Inc. or Company) (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended September 30, 2025, highlighting continued capital-efficient execution at a time when... More
